Wang Shaowen, Li Yongzhi, Sun Xiaoting, Song Tianping, Wang You, Xue Ziyue, Guo Yang, Wang Jiawei, Cui Zhijia, Lu Peijian, Huang Haifeng, Pan Diqing, Xu Dali, You Shuailin, Liu Wei, Wang Tianlin, Yang Huazhe, Liu Yili
The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Department of Urology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Mater Today Bio. 2025 Aug 3;34:102165. doi: 10.1016/j.mtbio.2025.102165. eCollection 2025 Oct.
Genitourinary neoplasms, accounting for 20-25 % of all malignant tumors, are associated with high mortality rates and pose significant challenges to clinical treatment. Especially for young patients who have reproductive demands, pharmacotherapy is a promising non-surgical strategy to improve the survival rate and quality of life. However, the distinctive interface between physiological milieu complicates effective drug delivery. Nanomedicines offer distinct advantages, including mitigating clearance, enabling precise tumor targeting, and intracellular drug delivery. Unlike most reviews about the area, which focused on a specified tumor or nanomedicine, this review, for the first time, systematically summarized the application of extensively investigated nanomedicines in the entire genitourinary neoplasms, and provided the latest and most comprehensive insights. Furthermore, we proposed the shortage of therapeutic activity and challenges in nano-therapy, and highlighted the potential of innovative and functional nanomedicines as well as emerging technology.
泌尿生殖系统肿瘤占所有恶性肿瘤的20%-25%，死亡率高，给临床治疗带来重大挑战。特别是对于有生殖需求的年轻患者，药物治疗是一种有前景的非手术策略，可提高生存率和生活质量。然而，生理环境之间独特的界面使有效的药物递送变得复杂。纳米药物具有明显优势，包括减轻清除、实现精确的肿瘤靶向和细胞内药物递送。与大多数关于该领域的综述不同，后者侧重于特定的肿瘤或纳米药物，本综述首次系统总结了广泛研究的纳米药物在整个泌尿生殖系统肿瘤中的应用，并提供了最新和最全面的见解。此外，我们提出了纳米治疗中治疗活性的不足和挑战，并强调了创新和功能性纳米药物以及新兴技术的潜力。
